Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
116.96%
-
Total 13F principal
-
$261,971,087
-
Principal change
-
+$4,093,500
-
Total reported market value
-
$306,514,595
-
Number of holders
-
25
-
Value change
-
+$5,146,358
-
Number of buys
-
11
-
Number of sells
-
11
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2021
As of 30 Jun 2021,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$261,971,087
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, FRANKLIN RESOURCES INC, LAZARD ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, CAPSTONE INVESTMENT ADVISORS, LLC, PUTNAM INVESTMENTS LLC, Nuveen Asset Management, LLC, MORGAN STANLEY, ROYAL BANK OF CANADA, and DeepCurrents Investment Group LLC.
This page lists
25
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.